Veru Inc. (NASDAQ:VERU) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET
Company Participants
Sam Fisch - Executive Director, Investor Relations & Corporate Communications
Mitchell Steiner - Chairman, Chief Executive Officer & President
Michele Greco - Chief Financial Officer & Chief Accounting Officer
Dr. Gary Barnett - Chief Scientific Officer
Michael Purvis - Executive Vice President, General Counsel and Corporate Strategy
Conference Call Participants
Operator
Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded.
I would now like to turn the conference call over to Mr. Sam Fisch, Veru Inc.'s Executive Director, Investor Relations and Corporate Communications. Please go ahead.
Sam Fisch
Good morning. The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances, and development, and product portfolio.
Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings, as well as in our press releases from time to time.
I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc's, Chairman, CEO, and President.
Mitchell Steiner
Good morning. With me on this morning's call are Dr. Gary Barnett, Chief Scientific Officer; Michele Greco, the Chief Financial Officer, Chief Administration Officer; Michael Purvis, Executive Vice President, General Counsel and Corporate Strategy; and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you all for joining our call.
Veru Inc. is a late-stage clinical biopharmaceutical company focused on developing novel medicines for the treatment of advanced breast cancer and for acute respiratory distress syndrome related to viral lung infections. Our drug development program includes Enobosarm, a selective angioreceptor agonist for the treatment of second-line hormone-receptive-positive, HER2-negative metastatic breast cancer, and sabizabulin, a microtubule disruptor for the treatment of hospitalized COVID-19 and other types of viral-related ARDS.
The company also has an FDA-approved commercial product, the FC2 female condom, internal condom, but a dual protection against unplanned pregnancy and sexually transmitted infections. The revenue from the sexual health program is being used to partially fund the clinical development of our late-stage therapeutic candidates, which aim to address multi-billion-dollar premium market opportunities. We've had a very busy and productive third quarter fiscal year 2023. This morning, we will provide an update on the clinical development of breast cancer and viral ARDS drug candidates, as well as the good progress on the commercialization of our FC2 product.